Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Smith

Neurological Surgery Charlotte, NC Medical Doctor

NPI 1750380580 CMS profile 352055

225 Baldwin Ave, Charlotte, NC 28204

Open in the dashboard

General payments

$25,296

94 records reported · program years 2019–2025

Research payments

$3,000

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Smith of Charlotte, NC is reported in the CMS Open Payments database as having received $25,296 across 94 general payments and $3,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,310 17
2024 General $4,578 14
2024 Research $3,000 10
2023 General $4,268 20
2022 General $10,727 19
2021 General $52 2
2020 General $79 3
2019 General $282 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Smith
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Mark Smith were reported at $5,310. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Mark Smith Neurological Surgery median Middle half National median
2019 $282 $582 $138–$3,006 $163
2020 $79 $294 $76–$2,174 $114
2021 $52 $387 $105–$2,432 $132
2022 $10,727 $542 $139–$2,989 $149
2023 $4,268 $534 $145–$2,697 $160
2024 $4,578 $574 $155–$3,046 $164
2025 $5,310 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spine Wave, Inc. $21,603 37 payments
  2. Globus Medical, Inc. $1,128 10 payments
  3. Stryker Corporation $772 8 payments
  4. Cerapedics, Inc. $759 4 payments
  5. Medtronic, Inc. $285 7 payments
  6. DePuy Synthes Sales Inc. $174 5 payments
  7. Intrinsic Therapeutics $160 1 payment
  8. Arbor Pharmaceuticals, Inc. $131 9 payments
  9. NuVasive, Inc. $91 4 payments
  10. Medtronic USA, Inc. $73 3 payments
  11. Other $120 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,250 17 payments
  2. Food and Beverage $3,103 54 payments
  3. Royalty or License $2,510 4 payments
  4. Travel and Lodging $2,303 10 payments
  5. Education $131 9 payments
Products named General payments · program years 2019–2025
  1. SALVO SPINE SYSTEM Spinal Medical Device $9,941 12 payments
  2. SALVO SPINE SYSTEM Spinal Medical Device $6,260 9 payments
  3. ExcelsiusGPS Robotic Navigation System $1,059 6 payments
  4. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $759 4 payments
  5. SALVO SPINE SYSTEM Spinal Medical Device $347 4 payments
  6. ES2 SPINAL SYSTEM $175 1 payment
  7. AVS ANCHOR-L $172 1 payment
  8. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $160 1 payment
  9. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $160 1 payment
  10. CAPRI CORPECTOMY CAGE SYSTEM $157 1 payment
  11. Other $1,672 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Intrinsic Therapeutics $3,000 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

130

Median for Neurosurgery: 83

Drug cost

$849

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 61 $517
Methylprednisolone Generic 18 $123
Tizanidine Hcl Generic 21 $104
Methocarbamol Generic 13 $85
Meloxicam Generic 17 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$200,316

Medicare's payments for the services billed

Medicare patients

364

Average age 73

Services billed

943

205 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 73%
Ischemic heart disease 27%
Diabetes 25%
Depression 22%
Chronic kidney disease 19%
Osteoporosis 19%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record